{"id":15576,"date":"2021-11-24T10:43:39","date_gmt":"2021-11-24T10:43:39","guid":{"rendered":"https:\/\/rayner.com\/us\/blog\/rayner-appoints-vp-corporate-development-to-lead-global-commercial-expansion\/"},"modified":"2021-12-03T16:08:40","modified_gmt":"2021-12-03T16:08:40","slug":"rayner-appoints-vp-corporate-development-to-lead-global-commercial-expansion","status":"publish","type":"post","link":"https:\/\/rayner.com\/us\/rayner-appoints-vp-corporate-development-to-lead-global-commercial-expansion\/","title":{"rendered":"Rayner appoints VP Corporate Development to lead global commercial expansion"},"content":{"rendered":"<p><strong>NOVEMBER 24, 2021<\/strong>\u00a0\u2013 Worthing, United Kingdom. Rayner, a leading ophthalmology company focused on optimising visual outcomes for patients and surgeons, today announced the appointment of Dr Rob Nadler to the role of VP Corporate Development. Dr Nadler will play a critical role on the executive team, overseeing the company\u2019s M&amp;A strategy and brings invaluable clinical, strategic and financial experience to this task.<\/p>\n<p>\u201cThe addition of Rob strengthens our leadership team as Rayner is on the cusp of a key inflection point under new ownership. We continue our expansion into the US and China with recent approvals of RayOne EMV and RayOne Aspheric respectively, our continued \u2018go-direct\u2019 strategy and year-on-year growth in our broader premium and monofocal IOL portfolios,\u201d said Tim Clover, Chief Executive Officer of Rayner. \u201cRob brings an extensive track record in the industry, having been involved as a banker in many of the recent transactions in the space, and together with his background as an ophthalmic surgeon, brings a unique view to our future growth strategy.\u201d<\/p>\n<p>Dr Nadler added: \u201cHaving known the company and management team for several years, and seen and used their products in surgery, I have been impressed with Rayner\u2019s long history in the sector and the disruptive technology that continues to differentiate it from its peers. I am excited about the opportunity to help continue building the company.\u201d<\/p>\n<p>Dr Nadler spent over a decade advising healthcare companies on strategic and financial matters. He was previously at William Blair where he was the Head of Medtech in Europe. Prior to William Blair, Dr Nadler was a member of the Global Healthcare M&amp;A teams at Perella Weinberg Partners, Nomura and commenced his banking career at Lehman Brothers. He holds a medical and science degree from Imperial College and trained as an ophthalmic surgeon practicing in the UK.<\/p>\n<p>END<\/p>\n<p><strong>\u00a0<\/strong><\/p>\n<p><strong>About Rayner<\/strong><\/p>\n<p>Since the implantation of the first\u00a0Rayner\u00a0intraocular lens by Sir Harold Ridley 1949, Rayner has continuously pioneered intraocular lens (IOL) design with a goal to improve vision and restore sight\u00a0worldwide. Today, Rayner\u2019s mission remains to deliver innovative and clinically superior ophthalmic products that respond to the expectations of our global customers to improve the sight and quality of life of their patients.<\/p>\n<p>Headquartered in Worthing, United Kingdom, Rayner markets its IOL, OVD, dry eye\u00a0and digital health portfolio worldwide\u00a0in over 80 countries through a network of distributors, with direct sales teams in the United Kingdom, USA, Germany, Austria, Switzerland, Italy, India,\u00a0Spain\u00a0and Portugal.<\/p>\n<p><strong>For\u00a0further information and media enquiries, please contact Rayner: <\/strong><a href=\"mailto:marketingteam@rayner.com\"><strong><span style=\"color: #339966;\">marketingteam@rayner.com<\/span><\/strong><\/a><\/p>\n<p>EC 2021-89 11\/21<\/p>\n","protected":false},"excerpt":{"rendered":"<p>NOVEMBER 24, 2021\u00a0\u2013 Worthing, United Kingdom. Rayner, a leading ophthalmology company focused on optimising visual outcomes for patients and surgeons, today announced the appointment of Dr Rob Nadler to the role of VP Corporate Development. Dr Nadler will play a critical role on the executive team, overseeing the company\u2019s M&amp;A strategy and brings invaluable clinical,<\/p>\n","protected":false},"author":6,"featured_media":14330,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[942,946],"tags":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Rayner appoints VP Corporate Development to lead global commercial expansion - Rayner : USA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/rayner.com\/us\/rayner-appoints-vp-corporate-development-to-lead-global-commercial-expansion\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rayner appoints VP Corporate Development to lead global commercial expansion - Rayner : USA\" \/>\n<meta property=\"og:description\" content=\"NOVEMBER 24, 2021\u00a0\u2013 Worthing, United Kingdom. Rayner, a leading ophthalmology company focused on optimising visual outcomes for patients and surgeons, today announced the appointment of Dr Rob Nadler to the role of VP Corporate Development. Dr Nadler will play a critical role on the executive team, overseeing the company\u2019s M&amp;A strategy and brings invaluable clinical,\" \/>\n<meta property=\"og:url\" content=\"https:\/\/rayner.com\/us\/rayner-appoints-vp-corporate-development-to-lead-global-commercial-expansion\/\" \/>\n<meta property=\"og:site_name\" content=\"Rayner : USA\" \/>\n<meta property=\"article:published_time\" content=\"2021-11-24T10:43:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-12-03T16:08:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/rayner.com\/us\/wp-content\/uploads\/sites\/5\/2021\/11\/Rob-Nadler.png\" \/>\n\t<meta property=\"og:image:width\" content=\"566\" \/>\n\t<meta property=\"og:image:height\" content=\"406\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"kevin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"kevin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/rayner.com\/us\/rayner-appoints-vp-corporate-development-to-lead-global-commercial-expansion\/\",\"url\":\"https:\/\/rayner.com\/us\/rayner-appoints-vp-corporate-development-to-lead-global-commercial-expansion\/\",\"name\":\"Rayner appoints VP Corporate Development to lead global commercial expansion - Rayner : USA\",\"isPartOf\":{\"@id\":\"https:\/\/rayner.com\/us\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/rayner.com\/us\/rayner-appoints-vp-corporate-development-to-lead-global-commercial-expansion\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/rayner.com\/us\/rayner-appoints-vp-corporate-development-to-lead-global-commercial-expansion\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/rayner.com\/us\/wp-content\/uploads\/sites\/5\/2021\/11\/Rob-Nadler.png\",\"datePublished\":\"2021-11-24T10:43:39+00:00\",\"dateModified\":\"2021-12-03T16:08:40+00:00\",\"author\":{\"@id\":\"https:\/\/rayner.com\/us\/#\/schema\/person\/e8c292782c2fa4364d3a3829546f7118\"},\"breadcrumb\":{\"@id\":\"https:\/\/rayner.com\/us\/rayner-appoints-vp-corporate-development-to-lead-global-commercial-expansion\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/rayner.com\/us\/rayner-appoints-vp-corporate-development-to-lead-global-commercial-expansion\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/rayner.com\/us\/rayner-appoints-vp-corporate-development-to-lead-global-commercial-expansion\/#primaryimage\",\"url\":\"https:\/\/rayner.com\/us\/wp-content\/uploads\/sites\/5\/2021\/11\/Rob-Nadler.png\",\"contentUrl\":\"https:\/\/rayner.com\/us\/wp-content\/uploads\/sites\/5\/2021\/11\/Rob-Nadler.png\",\"width\":566,\"height\":406},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/rayner.com\/us\/rayner-appoints-vp-corporate-development-to-lead-global-commercial-expansion\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/rayner.com\/us\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rayner appoints VP Corporate Development to lead global commercial expansion\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/rayner.com\/us\/#website\",\"url\":\"https:\/\/rayner.com\/us\/\",\"name\":\"Rayner : USA\",\"description\":\"Rayner is a British manufacturer of ophthalmic medical products, including intraocular lenses (IOLs) and eye drops to support ocular health\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/rayner.com\/us\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/rayner.com\/us\/#\/schema\/person\/e8c292782c2fa4364d3a3829546f7118\",\"name\":\"kevin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/rayner.com\/us\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ae78b6bc633ebd51238ea3bb16f6968b?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ae78b6bc633ebd51238ea3bb16f6968b?s=96&d=mm&r=g\",\"caption\":\"kevin\"},\"url\":\"https:\/\/rayner.com\/us\/author\/kevin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Rayner appoints VP Corporate Development to lead global commercial expansion - Rayner : USA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/rayner.com\/us\/rayner-appoints-vp-corporate-development-to-lead-global-commercial-expansion\/","og_locale":"en_GB","og_type":"article","og_title":"Rayner appoints VP Corporate Development to lead global commercial expansion - Rayner : USA","og_description":"NOVEMBER 24, 2021\u00a0\u2013 Worthing, United Kingdom. Rayner, a leading ophthalmology company focused on optimising visual outcomes for patients and surgeons, today announced the appointment of Dr Rob Nadler to the role of VP Corporate Development. Dr Nadler will play a critical role on the executive team, overseeing the company\u2019s M&amp;A strategy and brings invaluable clinical,","og_url":"https:\/\/rayner.com\/us\/rayner-appoints-vp-corporate-development-to-lead-global-commercial-expansion\/","og_site_name":"Rayner : USA","article_published_time":"2021-11-24T10:43:39+00:00","article_modified_time":"2021-12-03T16:08:40+00:00","og_image":[{"width":566,"height":406,"url":"https:\/\/rayner.com\/us\/wp-content\/uploads\/sites\/5\/2021\/11\/Rob-Nadler.png","type":"image\/png"}],"author":"kevin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"kevin","Estimated reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/rayner.com\/us\/rayner-appoints-vp-corporate-development-to-lead-global-commercial-expansion\/","url":"https:\/\/rayner.com\/us\/rayner-appoints-vp-corporate-development-to-lead-global-commercial-expansion\/","name":"Rayner appoints VP Corporate Development to lead global commercial expansion - Rayner : USA","isPartOf":{"@id":"https:\/\/rayner.com\/us\/#website"},"primaryImageOfPage":{"@id":"https:\/\/rayner.com\/us\/rayner-appoints-vp-corporate-development-to-lead-global-commercial-expansion\/#primaryimage"},"image":{"@id":"https:\/\/rayner.com\/us\/rayner-appoints-vp-corporate-development-to-lead-global-commercial-expansion\/#primaryimage"},"thumbnailUrl":"https:\/\/rayner.com\/us\/wp-content\/uploads\/sites\/5\/2021\/11\/Rob-Nadler.png","datePublished":"2021-11-24T10:43:39+00:00","dateModified":"2021-12-03T16:08:40+00:00","author":{"@id":"https:\/\/rayner.com\/us\/#\/schema\/person\/e8c292782c2fa4364d3a3829546f7118"},"breadcrumb":{"@id":"https:\/\/rayner.com\/us\/rayner-appoints-vp-corporate-development-to-lead-global-commercial-expansion\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/rayner.com\/us\/rayner-appoints-vp-corporate-development-to-lead-global-commercial-expansion\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/rayner.com\/us\/rayner-appoints-vp-corporate-development-to-lead-global-commercial-expansion\/#primaryimage","url":"https:\/\/rayner.com\/us\/wp-content\/uploads\/sites\/5\/2021\/11\/Rob-Nadler.png","contentUrl":"https:\/\/rayner.com\/us\/wp-content\/uploads\/sites\/5\/2021\/11\/Rob-Nadler.png","width":566,"height":406},{"@type":"BreadcrumbList","@id":"https:\/\/rayner.com\/us\/rayner-appoints-vp-corporate-development-to-lead-global-commercial-expansion\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/rayner.com\/us\/"},{"@type":"ListItem","position":2,"name":"Rayner appoints VP Corporate Development to lead global commercial expansion"}]},{"@type":"WebSite","@id":"https:\/\/rayner.com\/us\/#website","url":"https:\/\/rayner.com\/us\/","name":"Rayner : USA","description":"Rayner is a British manufacturer of ophthalmic medical products, including intraocular lenses (IOLs) and eye drops to support ocular health","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/rayner.com\/us\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-GB"},{"@type":"Person","@id":"https:\/\/rayner.com\/us\/#\/schema\/person\/e8c292782c2fa4364d3a3829546f7118","name":"kevin","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/rayner.com\/us\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ae78b6bc633ebd51238ea3bb16f6968b?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ae78b6bc633ebd51238ea3bb16f6968b?s=96&d=mm&r=g","caption":"kevin"},"url":"https:\/\/rayner.com\/us\/author\/kevin\/"}]}},"_links":{"self":[{"href":"https:\/\/rayner.com\/us\/wp-json\/wp\/v2\/posts\/15576"}],"collection":[{"href":"https:\/\/rayner.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/rayner.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/rayner.com\/us\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/rayner.com\/us\/wp-json\/wp\/v2\/comments?post=15576"}],"version-history":[{"count":0,"href":"https:\/\/rayner.com\/us\/wp-json\/wp\/v2\/posts\/15576\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/rayner.com\/us\/wp-json\/wp\/v2\/media\/14330"}],"wp:attachment":[{"href":"https:\/\/rayner.com\/us\/wp-json\/wp\/v2\/media?parent=15576"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/rayner.com\/us\/wp-json\/wp\/v2\/categories?post=15576"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/rayner.com\/us\/wp-json\/wp\/v2\/tags?post=15576"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}